Genetic and pharmacological reduction of CDK14 mitigates synucleinopathy
Jean-Louis A. Parmasad, Konrad M. Ricke, Benjamin Nguyen, Morgan G. Stykel, Brodie Buchner-Duby, Amanda Bruce, Haley M. Geertsma, Eric Y. Lian, Nathalie A. Lengacher, Steve M. Callaghan, Alvin P. Joselin, Julianna J. Tomlinson, Michael G. Schlossmacher, William L. Stanford, Jiyan Ma, , Maxime W.C. Rousseaux
This study shows that reducing CDK14 genetically or pharmacologically decreases alpha-synuclein pathology and improves symptoms in Parkinson's disease models.
Cell Death and Disease · Apr 4, 2024Peer-reviewedNeuroscience